Financing - April 10, 2019
Biovica completes a directed new share issue of SEK 60 million
The company has resolved to carry out a directed new share issue of Class B Shares at a subscription price of SEK 10 per share. The directed new share issue was substantially over-subscribed with large interest from institutional investors in the Nordics and Europe. Through the directed new share issue and subject to the approval of […]
Clinical Trials - November 23, 2017
New study results from Biovica
In collaboration with University of Heidelberg, Germany, results from a clinical study of pancreatic cancer is published in the Pancreas scientific journal. The results demonstrate that Biovica’s DiviTum assay can provide an accurate prognosis and evaluation of treatment efficacy. The proof of concept study, including 404 patients, provides evidence for using DiviTum as a dynamic […]
Acquisition - May 17, 2016
Biovica acquires cSens
Biovica has acquired cSens, a company that has developed a PCR-based platform for the analysis of serum thymidine kinase (TK) enzyme activity, which correspond to tumor proliferation and cancer aggressiveness. The cSens technology complements Biovica’s current TK assay DiviTum ™, which is currently included in clinical studies with leading cancer institutes throughout the world. The […]
Clinical Trials - June 27, 2015
Biovica Project Earns EC Funding
Biovica has been selected by the European Commission to receive support for a project as part of the Horizon 2020 phase 2 program. Biovica’s project “Clinical validation of the DiviTum assay in two high profile clinical studies in Europe” is receiving € 682,000 and being undertaken with a European cancer study group and Karolinska Institutet, […]
